Eleventh Circuit Hears Case Addressing Qui Tam Realtor Constituti

Why This Eleventh Circuit Case Matters

The Eleventh Circuit’s review of United States ex rel. Zafirov v. Florida Medical Associates has become one of the most closely watched False Claims Act cases in the country. At first glance, the dispute may sound like a technical fight about old Latin words, federal procedure, and constitutional clauses that most people last encountered during a stressful civics exam. But the stakes are enormous.

The case asks whether private whistleblowers, known as qui tam relators, may continue bringing fraud lawsuits in the name of the federal government when the Department of Justice declines to take over the case. If the answer is no, a major engine of federal fraud enforcement could be dramatically weakened. If the answer is yes, the False Claims Act’s whistleblower system may survive another constitutional challenge and keep humming along like a very expensive fraud-detection machine.

The issue has drawn national attention because qui tam lawsuits are not a side alley in federal enforcement. They are a main road. Whistleblowers regularly expose alleged fraud in Medicare, Medicaid, defense contracting, government procurement, pandemic relief programs, customs duties, and federal grants. The False Claims Act allows the government to recover treble damages and civil penalties from those who knowingly submit false claims or cause false claims to be submitted to the United States.

What Is a Qui Tam Relator?

A qui tam relator is a private person who files a lawsuit on behalf of the federal government under the False Claims Act. The phrase “qui tam” comes from a longer Latin expression meaning that the person sues for the sovereign as well as for himself. In modern terms, think of the relator as a whistleblower-plaintiff: someone who claims to have information about fraud against the government and asks a federal court to hold the alleged wrongdoer accountable.

The False Claims Act gives relators a financial incentive to come forward. If the case succeeds, the relator may receive a share of the recovery. When the government intervenes and litigates the case, the relator’s share is generally lower. When the government declines to intervene and the relator carries the case forward alone, the potential share is higher. The policy idea is simple: people inside complex organizations often see misconduct before prosecutors do. A billing clerk, physician, coder, contractor employee, or compliance officer may notice patterns that never appear on a government spreadsheet until someone points them out.

That incentive structure is why the False Claims Act is often called the government’s most powerful civil anti-fraud statute. It combines private information with public enforcement. The government gets a tip, the relator gets a possible reward, and defendants get litigation that can feel like being chased by both a watchdog and a tax collector wearing the same hat.

The Zafirov Case: A Medicare Fraud Suit Becomes a Constitutional Showdown

The Eleventh Circuit case arose from allegations by Dr. Clarissa Zafirov, who filed a False Claims Act suit against Florida Medical Associates and related health care entities. The underlying complaint accused the defendants of Medicare fraud involving diagnosis codes and alleged misrepresentations about patients’ medical conditions. The United States declined to intervene in the case, meaning the relator continued the litigation without the government taking primary control.

The defendants then advanced a constitutional argument that has been gaining momentum: when a private relator litigates in the name of the United States, seeks penalties, drives discovery, and attempts to recover money for the federal treasury, that person is exercising executive power. If so, the argument goes, the relator may qualify as an “Officer of the United States” under Article II of the Constitution. Officers must be appointed through constitutionally authorized methods. A private relator is not appointed by the President, a department head, or a court in the way Article II requires.

In September 2024, U.S. District Judge Kathryn Kimball Mizelle in the Middle District of Florida accepted that Appointments Clause argument and dismissed the case. Her ruling concluded that an FCA relator exercises significant authority under federal law and occupies a continuing position created by statute. Because Zafirov was not constitutionally appointed, the court held that she could not proceed as a relator. The district court did not need to reach other Article II arguments involving presidential control and removal authority.

That decision was extraordinary because courts had long allowed qui tam suits to proceed. While defendants have raised constitutional objections before, the Zafirov ruling gave those objections new force. It was not merely academic thunder in a law review cloud. It dismissed an actual FCA case and placed the Eleventh Circuit in position to decide whether one district court had spotted a constitutional defect hiding in plain sight for decades.

The Constitutional Question: Private Whistleblower or Federal Officer?

The heart of the dispute is the Appointments Clause. That clause controls how federal officers are appointed and is designed to preserve accountability in the executive branch. The defendants argue that a relator does more than report fraud. Once the government declines to intervene, the relator can conduct litigation, demand discovery, negotiate, pressure defendants, and seek remedies on behalf of the United States. In their view, that is not ordinary private litigation. It is delegated federal enforcement power.

The relator and the government see it differently. They argue that qui tam relators are private parties with a partial assignment of the government’s claim and a personal financial stake in the outcome. They do not hold a government office, draw a government salary, command federal employees, or bind the executive branch in the way a true officer can. The government also retains important statutory rights, including the ability to intervene, seek dismissal, object to settlements, and limit certain actions that would interfere with government interests.

This is where the case becomes more than a fight over labels. If a relator is just a private plaintiff, the FCA’s structure looks constitutionally ordinary. If a relator is an officer exercising executive power, the statute may have a serious problem. The difference between “private plaintiff with a bounty” and “unappointed federal prosecutor in sneakers” is doing a lot of work here.

Why the Supreme Court Is Hovering in the Background

The Eleventh Circuit is not operating in a vacuum. In 2023, the Supreme Court decided United States ex rel. Polansky v. Executive Health Resources, a case about when the government may dismiss a qui tam suit after initially declining to intervene. The Court held that the government may intervene later and seek dismissal, with courts evaluating the request under the ordinary voluntary dismissal standard.

Although Polansky did not decide the Article II issue, it placed the constitutional question under a bright spotlight. Justice Clarence Thomas wrote separately about serious constitutional concerns with the qui tam device. Justice Brett Kavanaugh, joined by Justice Amy Coney Barrett, also indicated that the Court should consider the Article II question in an appropriate case. That was not a holding, but it was a loud judicial doorbell. Lawyers heard it. Defendants heard it. The Zafirov case is one result.

The Supreme Court’s interest matters because a broad ruling against qui tam relators would reshape federal fraud enforcement nationwide. The Eleventh Circuit’s decision could either calm the waters, deepen a circuit split, or send the issue one step closer to Supreme Court review. In legal terms, the case is “important.” In practical terms, everyone with government money in their revenue stream should probably stop pretending this is background noise.

What Happened at the Eleventh Circuit Argument?

At oral argument, the Eleventh Circuit panel pressed all sides on the practical and constitutional consequences of the FCA’s qui tam structure. The judges examined whether relators exercise significant federal authority, whether the government’s retained control is enough to satisfy Article II, and whether historical practice supports the constitutionality of qui tam suits.

The government argued that the executive branch maintains sufficient control over FCA litigation. It can review the complaint during the seal period, decide whether to intervene, move to dismiss, object to settlements, and step in when government interests require it. From that perspective, a relator does not replace the executive branch. The relator operates within a statutory system where the government remains the real party in interest and keeps important supervisory tools.

The relator’s side emphasized that qui tam whistleblowers cannot force the government to do anything. They cannot command prosecutors, spend federal money, or bind the United States to policy decisions. They are private litigants with a statutory cause of action and a financial interest. In colorful terms, the argument is that the government may be in the passenger seat in some declined cases, but it still has access to the steering wheel, brakes, and emergency exit.

The defendants countered that control on paper is not the same as control in practice. When the government declines intervention, the relator may conduct years of litigation, impose discovery burdens, seek punitive-style remedies, and pressure settlement in the name of the United States. To the defendants, that looks like executive enforcement without constitutional appointment or presidential accountability.

Why Health Care Companies Are Watching Closely

Health care is the epicenter of False Claims Act enforcement. Medicare Advantage risk adjustment, diagnosis coding, medical necessity, kickbacks, prescription drugs, managed care, durable medical equipment, and laboratory billing are recurring FCA battlegrounds. The Zafirov case itself involves alleged Medicare coding misconduct, which makes it especially relevant for physician groups, insurers, hospitals, and health care investors.

If the Eleventh Circuit affirms the district court’s ruling, defendants in health care FCA cases may raise similar constitutional challenges more aggressively. Cases in which the government declined to intervene could be especially vulnerable because they present the cleanest version of the argument: a private relator, not the Department of Justice, is driving the lawsuit.

That does not mean every FCA case would vanish overnight. Government-intervened cases would remain different. The DOJ could still sue directly. Congress could attempt legislative fixes. Courts might limit any ruling to declined qui tam suits or to specific procedural circumstances. Still, even a narrow ruling could change litigation strategy, settlement leverage, and compliance risk calculations.

What This Means for Businesses and Compliance Teams

For companies that receive federal funds, the practical takeaway is not “relax, the Constitution might save us.” That is not a compliance plan; that is a wish wearing a necktie. The better takeaway is that FCA risk remains real, but the procedural environment is changing.

Organizations should continue strengthening internal reporting systems, auditing high-risk billing practices, documenting compliance decisions, and responding seriously to employee concerns. Many qui tam cases begin because insiders believe their warnings were ignored. A strong internal compliance culture can catch problems early, reduce damages, and sometimes prevent a frustrated employee from becoming a relator.

Companies should also reassess how they evaluate declined qui tam cases. Historically, a government declination often improved the defendant’s position, but it did not end the case. Relators could still proceed. If constitutional challenges gain traction, declined cases may become a more active battlefield for motions practice. Defense counsel will likely examine whether the relator’s role, the government’s level of participation, and the remedies sought create an Article II problem.

Possible Outcomes in the Eleventh Circuit

1. The Court Reverses and Upholds Qui Tam Relators

The Eleventh Circuit could reject the Appointments Clause challenge and hold that relators are private plaintiffs, not federal officers. This would preserve the traditional FCA structure and align with the long-standing acceptance of qui tam litigation. The court might emphasize history, congressional design, the relator’s private stake, and the government’s retained authority.

2. The Court Affirms the District Court

The court could agree that relators exercise significant federal authority and must be appointed under Article II. That would be a landmark ruling. It could invite immediate Supreme Court attention and trigger similar motions across the country. Plaintiffs’ lawyers would call it a threat to anti-fraud enforcement. Defendants would call it constitutional accountability. Both would be right about the importance.

3. The Court Issues a Narrow Decision

The Eleventh Circuit might avoid a sweeping ruling by focusing on waiver, remedy, statutory interpretation, or the specific posture of the case. A narrow decision could leave the biggest constitutional questions unresolved while still shaping future FCA litigation. Courts sometimes prefer a scalpel to a chainsaw, especially when a case touches a statute that has recovered billions for taxpayers.

Experiences and Practical Lessons From the Qui Tam Constitutionality Fight

For anyone who has worked around compliance, health care billing, government contracting, or internal investigations, the Zafirov case feels less like an abstract constitutional debate and more like a warning siren with legal footnotes. The lived experience of False Claims Act risk is usually not dramatic at first. It often begins with a spreadsheet, a coding pattern, an uncomfortable email, a billing shortcut, or an employee who says, “Are we sure this is allowed?” That question is small, but in FCA land, small questions can grow muscles.

One practical experience from FCA matters is that ignored internal concerns are dangerous. Employees rarely begin by wanting to become whistleblowers. Many start by asking supervisors for clarification. They may raise concerns about diagnosis codes, medical necessity, contract certifications, grant conditions, or documentation gaps. If the company responds defensively, dismissively, or with corporate jazz hands instead of a real review, trust breaks down. Once trust disappears, outside counsel, government hotlines, and qui tam complaints become more likely.

Another lesson is that government declination does not mean a case is harmless. Many executives hear “the DOJ declined to intervene” and assume the lawsuit is basically a deflated balloon. Not quite. A declined qui tam case can still produce years of discovery, legal fees, reputation risk, and settlement pressure. The Zafirov constitutional challenge matters because it attacks the legal authority of the relator in precisely that setting. But until appellate courts and possibly the Supreme Court settle the issue, companies should treat declined cases as serious litigation, not as paperwork with a nap schedule.

For compliance teams, the best experience-based strategy is boring in the best possible way: document decisions, train people, audit frequently, and create safe reporting channels. Boring compliance is often beautiful compliance. If a diagnosis code is supported, preserve the support. If a contract certification depends on a condition, identify who verified it and when. If a billing rule is ambiguous, document the legal interpretation. Good records do not guarantee victory, but they can turn a scary allegation into a manageable dispute.

For whistleblowers, the Zafirov case is a reminder that qui tam litigation is not simply “report fraud, receive check, buy celebratory sandwich.” FCA cases are complex, slow, and procedurally demanding. Relators must plead fraud with particularity, preserve confidentiality during the seal period, work with counsel, and prepare for aggressive defense strategies. The constitutional debate adds another layer: even a well-pleaded case may face challenges about whether the relator has authority to proceed.

For defendants, the experience is equally sobering. A constitutional motion may be powerful, but it should not distract from the facts. Courts still care whether claims were false, whether knowledge can be shown, whether the alleged misstatement was material, and whether damages are real. The best defense usually combines legal strategy with factual discipline. Constitutional arguments may shape the battlefield, but billing records, emails, contracts, and witness testimony still fight the war.

The broader lesson is that the False Claims Act sits at the intersection of money, power, and accountability. Qui tam relators can expose fraud the government might never discover alone. At the same time, defendants argue that private people should not wield federal enforcement power without constitutional safeguards. The Eleventh Circuit’s decision will not just answer a technical legal question. It will influence how fraud is reported, how companies manage compliance, and how the federal government protects public funds.

Conclusion

The Eleventh Circuit’s review of the Zafirov case could become a turning point for False Claims Act enforcement. The court must decide whether qui tam relators are private whistleblowers operating within a constitutional statutory framework or unappointed actors exercising executive power in violation of Article II. That question sounds narrow, but its consequences could reach hospitals, insurers, defense contractors, universities, importers, grant recipients, and every business that touches federal money.

For now, the safest assumption is that the FCA remains powerful, relator litigation remains active, and constitutional challenges are no longer fringe arguments. Businesses should strengthen compliance before a whistleblower appears. Relators should understand the procedural complexity before filing. And legal observers should keep their eyes on the Eleventh Circuit, because this case may help determine whether the qui tam system keeps marching forward or heads to the Supreme Court for its biggest test in decades.

SEO Tags